European Injectable Drug Delivery Market by Type, Therapeutic, Usage Pattern, Administration, End User - Forecast to 2020

The European injectable drug delivery market is expected to reach $207.3 billion by 2020 from $114.7 billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. The oncology segment is expected to witness the highest CAGR in the forecast period.

Factors such as rising incidences of chronic diseases, growth of the biologics market, demand of self-injection devices, and technological advancements, are driving the growth of the European injectable drug delivery market. In addition, Europe is emphasizing on innovation of formulations and improving the delivery of pharmaceuticals. For instance, in November 2012, COMPACT (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets), a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced the launch of a €30 million ($38.5 million) project, which focuses on improving the delivery of biopharmaceuticals. The consortium would address the major bottlenecks in the development of novel innovative medicines based on biological macromolecules, such as proteins/peptides and oligonucleotides. Such investments are fueling the growth of the market.

Germany is expected to be the fastest-growing country in the European injectable drug delivery market. High growth in this market can be attributed to the increased demand for injectable insulin and self-injection devices, particularly pen injectors which are used in the treatment of diabetes.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the European injectable drug delivery market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms to garner a greater market share. Firms purchasing the report can use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

‧ Market Penetration: Comprehensive information on the product portfolios of the top players in the European injectable drug delivery market. The report analyzes this market by type, therapeutic application, usage pattern, mode of administration, end user, and region
‧ Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the European injectable drug delivery market
‧ Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of leading players in the European injectable drug delivery market
‧ Market Development: Comprehensive information about lucrative markets. The report analyzes the market for various European injectable drug delivery across countries
‧ Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the European injectable drug delivery market

TABLE OF CONTENTS

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 MARKET SCOPE 24
1.3.1 MARKETS COVERED 24
1.3.2 YEARS CONSIDERED FOR THE STUDY 27
1.4 CURRENCY 28
1.5 LIMITATIONS 28
1.6 MARKET STAKEHOLDERS 28
2 RESEARCH METHODOLOGY 29
2.1 MARKET SIZE ESTIMATION 30
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.3 KEY DATA FROM SECONDARY SOURCES 34
2.4 KEY DATA FROM PRIMARY SOURCES 34
2.5 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 40
4.1 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION 40
4.2 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN 41
4.3 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER 42
4.4 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION 43
5 MARKET OVERVIEW 44
5.1 INTRODUCTION 45
5.2 MARKET SEGMENTATION 45
5.2.1 BY TYPE 46
5.2.2 BY THERAPEUTIC APPLICATION 46
5.2.3 BY USAGE PATTERN 47
5.2.4 BY MODE OF ADMINISTRATION 47
5.2.5 BY END USER 47
5.2.6 BY REGION 48
5.3 MARKET DYNAMICS 48
5.4 DRIVERS 50
5.4.1 RISING PREVALENCE OF CHRONIC DISEASES 50
5.4.2 INCREASE IN DEMAND FOR SELF –INJECTION DEVICES 50
5.4.3 GROWTH OF THE BIOLOGICS MARKET 51
5.4.4 TECHNOLOGICAL ADVANCEMENTS 51
5.5 RESTRAINTS 52
5.5.1 NEEDLESTICK INJURIES AND INFECTIONS 52
5.5.2 RISE OF ALTERNATE MODE OF DRUG DELIVERY 53
5.6 OPPORTUNITIES 54
5.6.1 INCREASE IN DEMAND FOR BIOSIMILARS AND GENERIC INJECTABLES 54
5.6.1.1 Biosimilars 54
5.6.1.2 Generic injectables 54
5.6.2 CONTRACEPTIVE INJECTABLES 54
5.7 CHALLENGES 55
5.7.1 PRODUCT RECALL 55
5.7.2 REGULATORY HURDLES 56
5.7.3 STABILITY OF THE PRODUCT 56
5.7.4 STERILITY OF INJECTIONS 56
6 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY TYPE 58
6.1 INTRODUCTION 59
6.2 DEVICES 60
6.2.1 CONVENTIONAL INJECTION DEVICES 62
6.2.1.1 By Material 64
6.2.1.1.1 Glass 65
6.2.1.1.2 Plastic 66
6.2.1.2 By Product 68
6.2.1.2.1 Fillable syringes 68
6.2.1.2.2 Prefilled syringes 70
6.2.1.3 By Usability 71
6.2.1.3.1 Reusable syringes 72
6.2.1.3.2 Disposable syringes 73
6.2.2 SELF-INJECTION DEVICES 74
6.2.2.1 Needle-free injectors 76
6.2.2.1.1 By product 78
6.2.2.1.1.1 Fillable needle-free injectors 79
6.2.2.1.1.2 Prefilled needle-free injectors 80
6.2.2.1.2 By technology 81
6.2.2.1.2.1 Jet-based needle-free injectors 82
6.2.2.1.2.2 Spring-based Needle-free injectors 83
6.2.2.1.2.3 Laser-powered needle-free injectors 84
6.2.2.1.2.4 Vibration-based needle-free injectors 86
6.2.2.1.3 By usability 87
6.2.2.1.3.1 Reusable needle-free injectors 88
6.2.2.1.3.2 Disposable needle-free injectors 89
6.2.2.2 Autoinjectors 90
6.2.2.2.1 By product 91
6.2.2.2.1.1 Fillable autoinjectors 92
6.2.2.2.1.2 Prefilled autoinjectors 93
6.2.2.2.2 By technology 95
6.2.2.2.2.1 Automated Autoinjectors 96
6.2.2.2.2.2 Manual Autoinjectors 97
6.2.2.2.3 By design 98
6.2.2.2.3.1 Standardized Autoinjectors 99
6.2.2.2.3.2 Customized Autoinjectors 101
6.2.2.2.4 By usability 102
6.2.2.2.4.1 Reusable autoinjectors 103
6.2.2.2.4.2 Disposable Autoinjectors 104
6.2.2.3 Pen injectors 105
6.2.2.3.1 By product 107
6.2.2.3.1.1 Single-chambered Pen Injectors 108
6.2.2.3.1.2 Dual-chambered Pen Injectors 109
6.2.2.3.2 By design 110
6.2.2.3.2.1 Standard Pen Injectors 111
6.2.2.3.2.2 Customized Pen Injectors 113
6.2.2.3.3 By usability 114
6.2.2.3.3.1 Reusable Pen Injectors 115
6.2.2.3.3.2 Disposable Pen Injectors 116
6.2.2.4 Wearable injectors 117
6.2.2.5 Other Devices 119
6.3 FORMULATIONS 120
6.3.1 CONVENTIONAL DRUG DELIVERY 121
6.3.1.1 SOLUTIONS 122
6.3.1.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS 123
6.3.1.3 SUSPENSIONS 124
6.3.1.4 EMULSIONS 125
6.3.2 NOVEL DRUG DELIVERY FORMULATIONS 125
6.3.2.1 COLLOIDAL DISPERSIONS 127
6.3.2.1.1 LIPOSOMES 128
6.3.2.1.2 NIOSOMES 129
6.3.2.1.3 POLYMERIC/MIXED MICELLE 129
6.3.2.1.4 NANOPARTICLES 130
6.3.2.1.4.1 NANOSUSPENSIONS 132
6.3.2.1.4.2 NANOEMULSIONS/MICROEMULSIONS 132
6.3.2.1.4.3 SOLID-LIPID NANOPARTICLES 133
6.3.2.2 MICROPARTICLES 134
6.3.2.2.1 MICROSPHERES 135
6.3.2.2.2 MICROCAPSULES 136
6.3.3 LONG-ACTING INJECTION FORMULATIONS 136
7 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION 138
7.1 INTRODUCTION 139
7.2 AUTOIMMUNE DISEASES 141
7.2.1 RHEUMATOID ARTHRITIS 143
7.2.2 MULTIPLE SCLEROSIS 143
7.2.3 CROHN’S DISEASE 144
7.2.4 PSORIASIS 145
7.2.5 OTHER AUTOIMMUNE DISEASES 146
7.3 HORMONAL DISORDERS 147
7.3.1 DIABETES 148
7.3.2 ANEMIA 149
7.3.3 REPRODUCTIVE HEALTH DISEASE 149
7.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 150
7.3.5 OSTEOPOROSIS 151
7.3.6 GROWTH HORMONE DEFICIENCY (GHD) 152
7.4 ORPHAN DISEASES 153
7.5 ONCOLOGY 154
7.6 OTHERS 155
7.6.1 PAIN MANAGEMENT 156
7.6.2 ALLERGY TREATMENT 157
7.6.3 AESTHETIC TREATMENT 158
7.6.4 HEPATITIS C 159
7.6.5 HEMOPHILIA 160
8 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN 161
8.1 INTRODUCTION 162
8.2 CURATIVE CARE 163
8.3 IMMUNIZATION 164
8.4 OTHERS (BLOOD TRANSFUSION AND BLOOD PRODUCTS AND CONTRACEPTIVES) 165
9 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION 166
9.1 INTRODUCTION 167
9.2 SKIN 168
9.3 CIRCULATORY/MUSCULOSKELETAL 169
9.4 ORGANS 170
9.5 CENTRAL NERVOUS SYSTEM 171
?
10 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY END USER 172
10.1 INTRODUCTION 173
10.2 HOSPITALS AND CLINICS 175
10.3 HOME CARE SETTINGS 176
10.4 RESEARCH LABORATORIES 176
10.5 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 177
10.6 OTHER END USERS 178
11 EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY 179
11.1 INTRODUCTION 180
11.1.1 GERMANY 181
11.1.2 FRANCE 185
11.1.3 U.K. 189
11.1.4 ITALY 193
11.1.5 SPAIN 197
11.1.6 REST OF EUROPE (ROE) 201
12 COMPETITIVE LANDSCAPE 206
12.1 OVERVIEW 206
12.2 MARKET SHARE ANALYSIS 207
12.3 COMPETITIVE SITUATIONS & TRENDS 208
12.3.1 NEW PRODUCT LAUNCHES 209
12.3.2 FDA APPROVALS 211
12.3.3 EXPANSIONS AND INVESTMENTS 212
12.3.4 ACQUISITIONS 212
12.3.5 COLLABORATIONS & AGREEMENTS 213
13 COMPANY PROFILES 214
13.1 INTRODUCTION 214
13.2 BAXTER INTERNATIONAL, INC. 215
13.3 BECTON, DICKINSON AND COMPANY 218
13.4 GERRESHEIMER AG 221
13.5 PFIZER, INC. 223
13.6 SCHOTT AG 226
13.7 ALKERMES PLC. 228
13.8 ELI LILLY AND COMPANY 230
13.9 SANDOZ 232
13.10 TERUMO CORPORATION 235
13.11 TEVA PHARMACEUTICAL INDUSTRIES LTD. 237
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
?
14 APPENDIX 239
14.1 INSIGHTS FROM INDUSTRY EXPERTS 239
14.2 DISCUSSION GUIDE 240
14.3 OTHER RECENT DEVELOPMENTS 244
14.4 AVAILABLE CUSTOMIZATIONS 245
14.5 RT: REAL-TIME MARKET INTELLIGENCE 245
14.6 RELATED REPORTS 246